Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12

Liquidia Corporation will report Q2 2025 financial results on August 12, 2025, with a webcast at 8:30 a.m. ET.

Quiver AI Summary

Liquidia Corporation, a biopharmaceutical company focused on therapies for rare cardiopulmonary diseases, announced it will release its second quarter 2025 financial results on August 12, 2025, followed by a webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. The webcast will be accessible on the company's website, with a rebroadcast available for one year. Liquidia specializes in developing treatments for pulmonary hypertension using its proprietary PRINT® Technology, including the approved drug YUTREPIA™ and the investigational L606 formulation of treprostinil. For further information, visit Liquidia's website or contact their investor and media relations representatives.

Potential Positives

Liquidia Corporation is set to report its second quarter 2025 financial results, which may provide insights into the company's financial health and growth potential.
The company is hosting a webcast to discuss financial results and corporate updates, indicating transparency and engagement with investors and stakeholders.
Liquidia's ongoing focus on developing innovative therapies, including YUTREPIA™ for pulmonary arterial hypertension, underscores its commitment to addressing unmet medical needs in rare cardiopulmonary diseases.
The development of L606, an investigational formulation of treprostinil, shows the company's continuing innovation and exploration of next-generation therapies in its market segment.

Potential Negatives

FAQ

When will Liquidia Corporation report its second quarter 2025 financial results?

Liquidia Corporation will report its second quarter 2025 financial results on August 12, 2025.

What time is the webcast for Liquidia's financial results?

The webcast will take place at 8:30 a.m. Eastern Time.

How can I access Liquidia's financial results webcast?

The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations.

What therapies is Liquidia Corporation focused on developing?

Liquidia is focused on developing innovative therapies for rare cardiopulmonary diseases, particularly pulmonary hypertension.

What is YUTREPIA™ and its approved use?

YUTREPIA™ is an inhalation powder approved for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD).

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$LQDA Insider Trading Activity

$LQDA insiders have traded $LQDA stock on the open market 30 times in the past 6 months. Of those trades, 0 have been purchases and 30 have been sales.

Here’s a breakdown of recent trading of $LQDA stock by insiders over the last 6 months:

ROGER JEFFS (Chief Executive Officer) has made 0 purchases and 4 sales selling 85,244 shares for an estimated $1,289,592.
MICHAEL KASETA (CFO and COO) has made 0 purchases and 4 sales selling 35,499 shares for an estimated $542,908.
RUSSELL SCHUNDLER (General Counsel) has made 0 purchases and 4 sales selling 23,183 shares for an estimated $351,846.
RAJEEV SAGGAR (Chief Medical Officer) has made 0 purchases and 5 sales selling 21,614 shares for an estimated $325,609.
SCOTT MOOMAW (Chief Commercial Officer) has made 0 purchases and 4 sales selling 15,440 shares for an estimated $237,398.
JASON ADAIR (Chief Business Officer) has made 0 purchases and 6 sales selling 9,389 shares for an estimated $145,912.
SARAH KREPP (Chief Human Resource Officer) sold 2,673 shares for an estimated $38,170
DANA BOYLE (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,256 shares for an estimated $37,807.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$LQDA Hedge Fund Activity

We have seen 85 institutional investors add shares of $LQDA stock to their portfolio, and 76 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

LM ADVISORS LLC removed 2,206,443 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $32,545,034
KYNAM CAPITAL MANAGEMENT, LP removed 1,632,526 shares (-72.0%) from their portfolio in Q1 2025, for an estimated $24,079,758
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 1,616,778 shares (+inf%) to their portfolio in Q1 2025, for an estimated $23,847,475
JANUS HENDERSON GROUP PLC added 1,103,799 shares (+206.1%) to their portfolio in Q1 2025, for an estimated $16,281,035
WHITEFORT CAPITAL MANAGEMENT, LP removed 937,065 shares (-47.2%) from their portfolio in Q1 2025, for an estimated $13,821,708
FMR LLC added 899,606 shares (+4360.0%) to their portfolio in Q1 2025, for an estimated $13,269,188
FARALLON CAPITAL MANAGEMENT LLC added 700,000 shares (+21.3%) to their portfolio in Q1 2025, for an estimated $10,325,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$LQDA Analyst Ratings

Wall Street analysts have issued reports on $LQDA in the last several months. We have seen 6 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Wells Fargo issued a "Overweight" rating on 06/12/2025
B of A Securities issued a "Buy" rating on 06/11/2025
Needham issued a "Buy" rating on 06/02/2025
Scotiabank issued a "Sector Outperform" rating on 05/28/2025
HC Wainwright & Co. issued a "Buy" rating on 05/28/2025
Oppenheimer issued a "Underperform" rating on 05/19/2025
Raymond James issued a "Strong Buy" rating on 05/09/2025

To track analyst ratings and price targets for $LQDA, check out Quiver Quantitative's $LQDA forecast page.

$LQDA Price Targets

Multiple analysts have issued price targets for $LQDA recently. We have seen 7 analysts offer price targets for $LQDA in the last 6 months, with a median target of $29.0.

Here are some recent targets:

Tiago Fauth from Wells Fargo set a target price of $25.0 on 06/12/2025
Jason Gerberry from B of A Securities set a target price of $23.0 on 06/11/2025
Serge Belanger from Needham set a target price of $32.0 on 06/02/2025
Greg Harrison from Scotiabank set a target price of $37.0 on 05/28/2025
Andrew Fein from HC Wainwright & Co. set a target price of $35.0 on 05/28/2025
Andreas Argyrides from Oppenheimer set a target price of $13.0 on 05/19/2025
Ryan Deschner from Raymond James set a target price of $29.0 on 05/09/2025

Full Release

MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations . A rebroadcast of the event will be available and archived for a period of one year at the same location.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT ^® Technology. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com .

Contact Information

Investors:
Jason Adair
Chief Business Officer
919.328.4350
[email protected]

Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
[email protected]